阿米巴痢疾、肝昏迷
Intestinal amebiasis: Treatment of acute and chronic intestinal amebiasis (not effective for extraintestinal amebiasis)
Hepatic coma: Management (adjunctive) of hepatic coma

Amebicide
Acts directly on ameba; has antibacterial activity against normal and pathogenic organisms in the GI tract; interferes with bacterial protein synthesis by binding to 30S ribosomal subunits

Absorption: Poor oral absorption
Excretion: Feces (~100% as unchanged drug)

1. Hypersensitivity to paromomycin or any component of the formulation
2. Intestinal obstruction

Paromomycin is poorly absorbed when given orally. Information is limited. Use may be considered for the treatment of giardiasis or cryptosporidiosis after the first trimester in pregnant women.

Paromomycin is poorly absorbed when given orally. Available information suggests that paromomycin may be used in nursing women when renal function is normal in both the mother and infant.

Common: Abdominal cramps, diarrhea, heartburn, nausea, vomiting
Postmarketing: Enterocolitis (secondary), eosinophilia, headache, ototoxicity, pruritus, steatorrhea, vertigo

Intestinal amebiasis: (PO) 25 to 35 mg/kg/day in 3 divided doses for 5 to 10 days
Hepatic coma: (PO) 4 g daily in divided doses (at regular intervals) for 5 to 6 days